TD Waterhouse Canada Inc. Trims Position in AbbVie Inc. $ABBV

TD Waterhouse Canada Inc. trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 27.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 366,299 shares of the company’s stock after selling 136,672 shares during the period. TD Waterhouse Canada Inc.’s holdings in AbbVie were worth $91,974,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Norges Bank bought a new stake in AbbVie during the fourth quarter valued at about $5,865,055,000. Corient Private Wealth LP bought a new position in shares of AbbVie in the second quarter worth about $559,736,000. Legal & General Group Plc purchased a new stake in shares of AbbVie during the second quarter worth about $2,905,952,000. Wellington Management Group LLP grew its position in shares of AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares in the last quarter. Finally, Capital World Investors raised its stake in AbbVie by 106.3% during the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock valued at $2,986,777,000 after purchasing an additional 6,736,161 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Qulipta migraine expansion: AbbVie reported positive Phase 3 LUNA results for atogepant (Qulipta) in preventing menstrual migraine. The treatment met its primary and secondary endpoints, potentially opening a new indication and supporting intermittent use rather than continuous daily dosing. This could expand Qulipta’s commercial opportunity and reinforce AbbVie’s position in migraine care. AbbVie’s migraine treatment meets late-stage study goal
• Positive Sentiment: Higher HSBC valuation: HSBC raised its price target for AbbVie to $315 from $300 while maintaining a Buy rating, signaling continued confidence in the company’s growth outlook and product pipeline. HSBC adjusts price target on AbbVie
• Positive Sentiment: Dividend maintained: AbbVie declared a quarterly cash dividend of $1.73 per share, payable Nov. 16 to shareholders of record Oct. 15. The unchanged payout supports the stock’s income appeal and reflects continued shareholder-return capacity. AbbVie declares quarterly dividend
• Neutral Sentiment: Pipeline and portfolio developments: Coverage highlighted the growth of Skyrizi and Rinvoq, the planned $10.9 billion Apogee Therapeutics acquisition, an ADARx collaboration and updated real-world data from an eye-implant study. These initiatives may diversify future growth, but their financial impact remains dependent on execution, approvals and clinical outcomes.
• Negative Sentiment: Regulatory setback: The FDA issued a Complete Response Letter for trenibotE, AbbVie’s fast-acting neurotoxin candidate. The action may delay the product’s launch and add uncertainty around the aesthetics pipeline. FDA issues Complete Response Letter for AbbVie’s trenibotE
• Negative Sentiment: Concentration and valuation concerns: Analysts continue to monitor AbbVie’s reliance on Skyrizi and the long-term effects of Humira’s patent-related decline. With the stock trading at a relatively elevated earnings multiple, execution risks and slower-than-expected diversification could limit further upside.

AbbVie Price Performance

NYSE ABBV opened at $255.00 on Friday. The stock has a market capitalization of $450.52 billion, a PE ratio of 72.03, a P/E/G ratio of 1.13 and a beta of 0.29. The business has a 50 day simple moving average of $254.54 and a two-hundred day simple moving average of $230.76. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts anticipate that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were paid a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s dividend payout ratio is presently 195.48%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price target for the company in a research note on Thursday, August 13th. Guggenheim lifted their price objective on shares of AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. JPMorgan Chase & Co. upped their target price on shares of AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Finally, BNP Paribas Exane lifted their price target on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $276.64.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by insiders.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.